Branded vs Generic Medicines: Margins & What to Stock

This covers the real margin structure at each level of the supply chain, why the incentive works the way it does, and how a pharmacy should actually decide what to stock rather than defaulting to whichever pushes hardest.

What margin does a branded medicine actually carry?

Retailer or chemist margin on branded medicines is fixed strictly around 16–20% in most cases, with stockist or distributor margin sitting lower still, generally 8–12%. The manufacturer's model behind branded medicines relies on a lower percentage margin per unit, offset by high volume and intensive medical marketing aimed at building doctor prescription loyalty rather than retailer incentive.

Price to the patient stays high under this model, controlled largely by brand equity and demand built through that marketing rather than by production cost alone. A peer-reviewed 2011 study specifically measured retailer margins on five branded medicines in the 25–30% range, somewhat above the commonly cited 16–20% figure, which suggests real-world margins vary by product and category rather than sitting at one fixed number across the board.

What margin does a generic or branded-generic medicine carry?

Generic and branded-generic medicines carry substantially higher retailer margins, commonly 20–50% or more, existing specifically to incentivise chemists to stock and actively recommend them. Distributor margin sits somewhat higher too, around 12–20%, compared to the 8–12% typical for branded stock.

The same 2011 study found something specifically worth knowing: retailer margin on the branded-generic version of a drug, made by the very same manufacturer as the branded original, ran higher than the branded version's own margin. This is the mechanism that makes generic substitution profitable for a chemist independent of any genuine clinical reasoning, and it's worth understanding precisely because it means the substitution incentive exists even when both products come from the same manufacturer and are chemically identical.

Why is the retailer margin so much higher on generics specifically?

Generic manufacturers spend far less on medical marketing and doctor-facing promotion than branded manufacturers do, and that saved cost gets redirected into retailer margin instead. It functions as a direct incentive to push the product at the counter where the actual sale happens.

Industry analysis puts India's all-generic manufacturer portfolios at 22–27% operating margins, notably above the pharmaceutical industry's general average. This shows the model works commercially even after paying out the higher retailer share.

This isn't necessarily a problem for the patient; generic medicines can cost 80–90% less than branded equivalents even after the retailer takes a considerably larger cut, so the patient often still comes out ahead in absolute terms. It does mean a chemist's recommendation carries a real financial incentive behind it that most patients never see or think to ask about.

What does this actually mean for what a pharmacy should stock?

A pharmacy's stocking decision shouldn't be driven purely by which category pays the pharmacy more. A strategy built solely around retailer margin, ignoring what patients and doctors in your area actually want, produces a pharmacy patients learn not to trust.

The commercially and clinically sound approach stocks both categories deliberately: branded medicines for patients whose doctors have specifically prescribed them by brand, and a solid generic range for patients seeking the lower-cost option, or for whom substitution is genuinely appropriate.

This dual approach also protects a pharmacy against a single-category disruption, whether a branded product goes off-patent and gets undercut by generics overnight, or a generic supplier's pricing shifts unexpectedly. Diversified stock is a hedge against exactly this kind of category-level volatility, independent of the margin question entirely.

What is the government's own position on trade margins?

The Department of Pharmaceuticals has directly investigated high trade margins in the pharmaceutical sector as a matter of public policy concern, given the gap between manufacturer cost and what patients ultimately pay at the counter.

This isn't a fringe concern. It's an official government inquiry into exactly the margin structure described above, reflecting real policy attention to how retailer incentives shape what gets recommended to patients at the counter.

For a pharmacy, this signals that margin-driven substitution practices sit under genuine regulatory attention, not just ethical debate, and building a stocking and recommendation policy that can withstand scrutiny is a sounder long-term position than optimising purely for retailer margin today.

Does this margin gap apply the same way to a hospital pharmacy?

A hospital pharmacy faces the same underlying margin structure, though the substitution decision involves a treating doctor's protocol more directly than a walk-in retail sale. Inpatient prescribing is generally more tightly controlled, though the margin incentive still exists at procurement level. A hospital pharmacy's purchasing decisions benefit from the same honest stocking logic: clinical appropriateness and doctor preference first, margin as a secondary consideration rather than the driving one.

Our pharmacy profit margin guide covers the broader margin picture beyond just the branded-versus-generic split, including where rent, staffing and expiry losses eat into whatever margin the stocking mix generates. Our inventory management guide covers the reorder discipline that keeps both categories moving without becoming dead stock, and our GST for pharmacy guide covers how tax treatment applies across both categories.

Do patients actually notice the substitution incentive?

Most patients don't, and that gap in awareness is precisely what makes the margin structure work commercially rather than provoking resistance at the counter. A patient handed a generic alternative with a confident explanation about identical active ingredients rarely questions it, and rightly so in most cases, since the clinical substance genuinely is often equivalent.

What patients rarely learn is that the chemist's confidence is backed by a real financial incentive as well as a clinical one, and the two motivations are impossible to separate from the patient's side of the counter. A pharmacy that's transparent about this, when asked, tends to build more durable trust over years of repeat business than one that never discloses it and eventually gets caught out by a patient who compares prices and notices the pattern themselves.

Sources

1. 1A comparative evaluation of price and quality of some off-patent medicines — National Institutes of Health, National Library of Medicine, Singal et al., 2011
2. 2High Trade Margin Report — Department of Pharmaceuticals, Government of India
3. 3National Pharmaceutical Pricing Authority — drug price control and margin regulation
4. 4Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
5. 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India

This article is for informational purposes and is not a substitute for professional medical or financial advice. Margin figures are industry estimates from cited sources and vary by product, region and distributor. Consult your prescribing doctor before substituting any medicine.